Skip to main content

Table 2 Baseline Characteristics of cohort stratified by azithromycin use

From: Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis

Factor Group Treatment P value
No-AZM AZM
N   96 29  
Age (years)   76.5 [67, 82.25] 70 [65, 81] 0.35
Sex M/F 66 (68.8)/30 (31.2) 19 (65.5)/10 (34.5) 0.821
Cirrhosis Yes 10 (10.4) 3 (10.3) 1
Sepsis pulmonary 55 (57.3) 23 (79.3) 0.048
Nonpulmonary 41 (42.7) 6 (20.7)
APACHE.II   23 [18, 26] 24 [21, 27] 0.462
McCabe 1/2/3 88 (91.7)/3 (3.1)/5 (5.2) 26 (89.7)/2 (6.9)/1 (3.4) 0.63
ARDS severity Mild 5 (5.2) 5 (17.2) 0.113
Moderate 45 (46.9) 13 (44.8)
Severe 46 (47.9) 11 (37.9)
SOFA   7 [5, 11] 9 [7, 12] 0.143
PaO2/FiO2   100.45 [70.97, 132.70] 114.20 [84.50, 180.00] 0.045
CT.score   214.05 [184.80, 265.60] 211.70 [188.10, 268.50] 0.667
Alb, g/dL   2.90 [2.58, 3.30] 2.50 [2.20, 3.00] 0.002
WBC   10,450 [5250, 14,400] 7300 [2300, 12,200] 0.055
C-reactive protein, mg/dL   15.33 [8.68, 25.07] 19.69 [10.22, 30.10] 0.239
Lactate dehydrogenase, IU/L   312 [248.25, 436.50] 301 [233.00, 434.00] 0.621
DIC score   2 [2, 4] 4 [2, 5] 0.028
FDP, mg/L   11.00 [6.72, 18.10] 11.90 [9.30, 20.00] 0.382
AntithrombinIII,  %   66.50 [52.75, 81.25] 65.00 [51.00, 79.00] 0.527
PLT,X104   18.35 [11.93, 28.30] 12.40 [7.70, 18.40] 0.003
D.dimer.μg/ml   5.95 [2.48, 11.00] 4.60 [3.10, 9.30] 0.398
Death (%)   48 (50.0) 10 (34.5) 0.202
  1. n (%), median [IQR]
  2. APACHE acute physiology and chronic health evaluation, ARDS acute respiratory distress syndrome, AZM azithromycin, DIC disseminated intravascular coagulation, FDP fibrin/fibrinogen degradation products, SOFA Sequential Organ Failure Assessment score